This medication can only be used by or on the advice of a veterinarian, as required by federal law.
Meloxicam use has been linked to acute renal failure and death in cats. Do not administer additional injectable or oral meloxicam to cats. See Contraindications,Warnings, and Precautions for detailed information.
Meloxicam is a member of the oxicam class of non-steroidal anti-inflammatory drugs (NSAIDs). Meloxicam equivalent to one milligram is present in each milliliter of METACAM Oral Suspension. 5 milligrams and sodium benzoate (1. 5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide. The formulation is a viscous yellowish suspension with a honey-like smell.
For the treatment of canine osteoarthritis-related pain and inflammation, METACAM Oral Suspension is recommended.
Always provide client information sheet with prescription. Before choosing to use METACAM, carefully weigh the potential benefits and risks compared to alternative treatment options. Use the smallest effective dose for the shortest time possible while taking into account each person’s response. METACAM Oral Suspension should be administered initially at 0. 09 mg/lb (0. only on the first day of treatment (2 mg/kg) body weight METACAM Oral Suspension should be administered once daily at a dose of 0 for all treatments beginning on day 2. 045 mg/lb (0. 1 mg/kg). The syringe is set up to deliver pounds of the daily maintenance dose.
Shake well before use, then remove cap. Particular attention should be paid to the precision of dosing Do not give drops directly into the mouth of small dogs in order to prevent accidental overdosing. Before serving the food to the dog, measure the suspension carefully to ensure that the right dose is given. The syringe provided with the meloxicam concentration of 1. For dogs weighing less than 5 lbs, doses exceeding 5 mg/mL must not be measured (2 3 kg).
For dogs less than 5 lbs (2. Using the dropper bottle, METACAM Oral Suspension can be administered to patients (up to 3 kg), one drop per pound of body weight for the 1 5 mg/mL concentration, applied topically to food (two drops for each kilogram of body weight).
METACAM Oral Suspension for dogs weighing 5 to 10 pounds can be administered orally using drops or the measuring syringe that comes with the package (see dosing instructions below). The syringe attaches to the bottle and is made to deliver the daily maintenance dose (0 mg), with a scale that starts at 5 lbs. 05 mg/lb or 0. 1 mg/kg). The weight of the dog should be rounded down to the nearest 5 pound increment before using the syringe. Replace and tighten cap after use.
Shake well before use then remove cap. You can either mix METACAM Oral Suspension with food or ingest it straight. Particular attention should be paid to the precision of dosing The measuring syringe included in the package can be used to administer METACAM Oral Suspension (see dosing instructions below). The syringe attaches to the bottle and has a weight scale for dispensing the daily maintenance dose (0.0). 05 mg/lb or 0. 1 mg/kg). The weight of the dog should be rounded down to the nearest 5 pound increment before using the syringe. As an alternative, METACAM Oral Suspension can be administered via dropper bottle, one drop for each pound of body weight for the 1 mg dose. Two drops for each kilogram of body weight at a concentration of 5 mg/mL Replace and tighten cap after use.
Dogs who are known to have meloxicam hypersensitivity should not take METACAM Oral Suspension. Do not use METACAM Oral Suspension in cats. Meloxicam use in cats has been linked to acute renal failure and death.
Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only.
Before beginning NSAID therapy, all dogs should have thorough physical and medical examinations as with any NSAID. Prior to and periodically throughout administration, appropriate laboratory testing to establish hematological and serum biochemical baseline data is advised. Owner should be given a client information sheet about METACAM and instructed to keep an eye out for any indications that their dog may be experiencing drug toxicity.
It has not been determined whether METACAM Oral Suspension can be used safely in canines under the age of six months, those used for breeding, or those who are lactating or pregnant. Since safety has not been established in canines with bleeding disorders, meloxicam is not advised for use in these animals.
As a class, cyclo-oxygenase inhibitory NSAIDs may cause liver, kidney, and gastrointestinal toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs who have had negative reactions to one NSAID may also have negative reactions to another NSAID. Patients who are dehydrated, taking concurrent diuretic therapy, or who already have renal, cardiovascular, and/or hepatic dysfunction are those who are most at risk for renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Patients with undiagnosed underlying or pre-existing disease may experience clinically significant disease as a result of such anti-prostaglandin effects. Concomitant use of other anti-inflammatory medications, such as NSAIDs or corticosteroids, should be avoided because NSAIDs have the potential to cause gastrointestinal ulcerations and/or perforations. When METACAM Oral Suspension has been administered in its entirety for the day, if more pain medication is still required, a non-NSAID or non-corticosteroid class of analgesia should be taken into consideration. The use of another NSAID is not recommended. When switching dogs from corticosteroid use or from one NSAID to another, take into account the proper washout intervals. Dogs have not been studied for the use of concurrent protein-bound medications with METACAM Oral Suspension. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The impact of concurrent medications that may impair METACAM Oral Suspension metabolism has not been assessed. Drug compatibility should be monitored in patients requiring adjunctive therapy.
Field safety was evaluated in 306 dogs. According to the findings of two studies, the most frequent negative effects related to the administration of meloxicam were GI abnormalities (vomiting, soft stools, diarrhea, and inappetence). The number of dogs who experienced adverse reactions during the studies is shown in the table below. During the course of the study, it’s possible that the adverse reaction occurred more than once in dogs.
Over a nine-year period, the following adverse reactions associated with the administration of meloxicam were reported: auto-immune hemolytic anemia in 1 dog, thrombocytopenia in 1 dog, polyarthritis in 1 dog, nursing puppy lethargy in 1 dog, and pyoderma in 1 dog.
Post-Approval Experience (Rev. 2010): Based on post-approval adverse drug experience reporting, the following adverse events are listed. Not all adverse reactions are reported to FDA/CVM. Using these data, it is not always possible to establish a causal link between product exposure and adverse event frequency or frequency of occurrence. The following negative events are listed by body system in decreasing order of frequency.
The adverse events mentioned above have been reported to have resulted in death. Meloxicam use in cats has been linked to acute renal failure and death.
Contact Boehringer Ingelheim Animal Health USA Inc. for assistance with reporting alleged adverse drug events, technical support, or to obtain a copy of the SDS. at 1-888-637-4251. Contact FDA at 1-888-FDA-VETS or online at www.ifadversedrugexperiencesforanimaldrugs.gov for more information. fda. gov/reportanimalae.
Like other medications in its class, METACAM can cause side effects. Owners should be made aware of the possibility of adverse reactions and the clinical symptoms linked to drug intolerance. Vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water intake, increased urination, pale gums from anemia, yellowing of the gums, skin, or whites of the eyes from jaundice, lethargy, uncoordination, seizures, or behavioral changes are some of the possible adverse reactions. This drug class’s serious side effects occasionally cause fatalities (see Adverse Reactions), and they can happen without warning. If intolerance symptoms are seen, owners should be advised to stop using METACAM and call their veterinarian right away. When the warning signs are identified, the medication is stopped, and veterinary care, if necessary, is started, the vast majority of patients who experience drug-related adverse reactions recover. Owners of all dogs should be informed of the value of routine follow-up while administering any NSAID.
Meloxicam has nearly 100% bioavailability when administered orally with food. Regardless of the route of administration, the terminal elimination half life after a single dose is estimated to be 24 hours (+/-30%). There is no proof that gender differences in drug pharmacokinetics are statistically significant. Up to five times the dosage advised for use in dogs, drug bioavailability, volume of distribution, and total systemic clearance remain unchanged. When dogs are dosed for 45 days or longer, there is some evidence of enhanced drug accumulation and a prolonged terminal elimination half-life.
Peak drug concentrations should happen in about 7 days. 5 hrs after oral administration. Corresponding peak concentration is approximately 0. 464 mcg/mL following a 0. 2 mg/kg oral dose. The drug is 97% bound to canine plasma proteins.
Two field studies involving a total of 277 dogs of various breeds, aged between six months and sixteen years, all with osteoarthritis, showed the efficacy of meloxicam. Both of the 14-day, masked, placebo-controlled studies were carried out. All dogs received 0. 2 mg/kg on day 1. All dogs were maintained on 0. 1 mg/kg of meloxicam orally every day between days 2 and 14 of both studies Lameness, weight-bearing, palpable pain, and general improvement were among the criteria that veterinarians evaluated. Owners evaluated mobility, the ability to stand up, limping, and general improvement. In the first field study (n=109), dogs received meloxicam for 14 days, and all parameters showed statistically significant clinical improvement. In the second field study (n=48), meloxicam-treated dogs showed clinical improvement for all parameters after 14 days of therapy; however, statistical significance was only shown for the overall investigator evaluation on day 7 and for the owner evaluation on day 14.
When veterinary professionals gave the first dose of METACAM Oral Suspension into the mouths of the dogs, all of the dogs accepted it. 90% of the dogs (123/136) accepted METACAM Oral Suspension when given by owners. Refusal to eat, difficulty swallowing, and salivation were issues related to administration.
Meloxicam was given orally at 1, 3, and 5X the recommended dose in a six-week target animal safety study, and no significant clinical adverse reactions occurred. All dose groups (control, 1, 3, and 5X the advised dose) of animals displayed some gastrointestinal distress (vomiting and diarrhea). Hematological, blood chemistry, urinalysis, clotting time, or buccal mucosal bleeding times did not show any treatment-related changes. One control dog, two dogs who received the 3X dose, and one dog who received the 5X dose all had stomach mucosal petechiae upon necropsy. Two dogs receiving the 5X dose and three dogs receiving the 1X dose both experienced areas of congested or depressed jejunal or ileal mucosa. In the control group, two additional dogs displayed comparable modifications. In dogs receiving the 3X dose, there were no macroscopic small intestinal lesions found. During the necropsy of two dogs given the 3X dose and two dogs given the 5X dose, renal enlargement was noted.
Three dogs at the 5X dose had minimal degeneration or light necrosis at the tip of the papilla, according to a microscopic examination of the kidneys. Microscopic analysis of the stomach revealed that two dogs receiving the recommended dose, three dogs receiving the 3X dose, and four dogs receiving the 5X dose all had inflammatory mucosal lesions, epithelial regenerative hyperplasia or atrophy, and submucosal gland inflammation. Small intestinal microscopic changes occasionally included mucosal congestion and tiny focal mucosal erosion affecting the villi. These lesions were seen in the jejunum of one dog treated with the recommended dose, one dog treated with the 5X dose, and the ileum of one control dog.
Meloxicam was given orally at 1, 3, and 5X the recommended dose in a six-month target animal safety study, and no significant clinical adverse reactions occurred. All animals showed some signs of gastrointestinal distress (diarrhea and vomiting) in all dose groups (controls, 1, 3, and 5X the recommended dose). Red blood cell counts were reduced in seven of 24 dogs (four 3X and three 5X dogs), the hematocrit was reduced in 18 of 24 dogs (including three control dogs), there was dose-related neutrophilia in one 1X, two 3X, and three 5X dogs, and there was evidence of regenerative anemia in two 3X and one 5X dog. Additionally, two 5X dogs’ BUN levels were elevated, and one 5X dog’s albumin level was lower.
Reddening of the gastric mucosal surface, which covered less than 25% of the surface area, was the main endoscopic change. Three dogs received the recommended dose, three received the 3X dose, and two received the 5X dose when this was observed. Two control dogs showed mucosal ulceration and reddening that covered less than 25% of the surface area.
Gross gastrointestinal necropsy findings included one dog receiving a 3X dose and one dog receiving a 5X dose that had mildly discolored stomach or duodenum. At the recommended dose in one dog and the 5X dose in another dog, multiple pinpoint red foci were seen in the gastric fundic mucosa.
Throughout the course of this six-month study, no dogs receiving meloxicam experienced any macroscopic or microscopic renal changes. Only one dog at the recommended dose and two dogs at the 3X dose had microscopic gastrointestinal findings. One dog’s duodenum was found to have a mild inflammatory mucosal infiltrate after receiving the recommended dosage. Two dogs who received the 3X dose showed mild fundic mucosa congestion and mild myositis of the stomach’s outer mural musculature.
METACAM Oral Suspension 1. 5 mg/mL dropper bottles with measuring syringes in 10, 32, 100, and 180 mL
Store between 68 and 77 degrees Fahrenheit (20 and 25 degrees Celsius) Excursions permitted between 59°F and 86°F (15°C and 30°C). If the mean kinetic temperature is no higher than 77°F (25°C), brief exposure to temperatures up to 104°F (40°C) may be tolerated; however, such exposure should be minimized.
This summary contains important information about METACAM. Before giving your dog METACAM, you should read this information. You should also read it again each time the prescription is renewed. This document is only intended to serve as a summary and is not intended to replace advice from your veterinarian. If you have questions about any of this information or want to learn more about METACAM, consult your veterinarian.
METACAM is a non-steroidal anti-inflammatory drug (NSAID) prescribed for the treatment of osteoarthritis in dogs. It reduces pain and inflammation (soreness). Your dog may exhibit the following changes or signs due to osteoarthritis (OA), a painful condition brought on by “wear and tear” of the cartilage and other joint components: limping or lameness, decreased activity or exercise (reluctance to stand, climb stairs, jump, or run, or difficulty performing these activities), stiffness or decreased joint movement. METACAM is given to dogs by mouth. Do not use METACAM Oral Suspension in cats. Meloxicam use in cats has been linked to acute renal failure and death.
METACAM can reduce pain and inflammation associated with osteoarthritis while also enhancing your dog’s mobility, even though it is not a treatment for OA.
• If METACAM is stopped or not administered as instructed, your dog’s discomfort and inflammation might return.
• Has experienced an allergic reaction to aspirin or other NSAIDs, such as hives, facial swelling, or red or itchy skin
People should not take METACAM. Keep METACAM and all medication out of reach of children. Call your physician immediately if you accidentally take METACAM.
Shake well before use, then remove cap. Particular attention should be paid to the precision of dosing
Do not give drops directly into the mouth of small dogs in order to prevent accidental overdosing.
Before serving the food to the dog, measure the suspension carefully to ensure that the right dose is given. The syringe provided with the meloxicam concentration of 1. For dogs weighing less than 5 lbs, doses exceeding 5 mg/mL must not be measured (2 3 kg).
For dogs less than 5 lbs (2. Using the dropper bottle, METACAM Oral Suspension can be administered to patients (up to 3 kg), one drop per pound of body weight for the 1 5 mg/mL concentration, applied topically to food (two drops for each kilogram of body weight).
METACAM Oral Suspension for dogs weighing 5 to 10 pounds can be administered orally using drops or the measuring syringe that comes with the package (see dosing instructions below). The syringe attaches to the bottle and is made to deliver the daily maintenance dose (0 mg), with a scale that starts at 5 lbs. 05 mg/lb or 0. 1 mg/kg). The weight of the dog should be rounded down to the nearest 5 pound increment before using the syringe. Replace and tighten cap after use.
Shake well before use then remove cap. You can either mix METACAM Oral Suspension with food or ingest it straight. Particular attention should be paid to the precision of dosing The measuring syringe included in the package can be used to administer METACAM Oral Suspension (see dosing instructions below). The syringe attaches to the bottle and has a weight scale for dispensing the daily maintenance dose (0.0). 05 mg/lb or 0. 1 mg/kg). The weight of the dog should be rounded down to the nearest 5 pound increment before using the syringe. As an alternative, METACAM Oral Suspension can be administered via dropper bottle, one drop for each pound of body weight for the 1 mg dose. Two drops for each kilogram of body weight at a concentration of 5 mg/mL Replace and tighten cap after use.
• All medications you are giving or intend to give your dog, including over-the-counter medications
METACAM, like other drugs, may cause some side effects. Dogs taking NSAIDs have been reported to experience severe but uncommon side effects. Serious side effects may appear with or without prior notice and, in rare circumstances, may be fatal.
The stomach, liver, and kidney problems that are most frequently associated with NSAID side effects are generally present. Keep an eye out for the following side effects that could indicate your dog has a problem with METACAM or another health issue:
If you believe your dog has a medical condition or is experiencing a side effect from METACAM therapy, it’s critical to stop treatment and call your veterinarian right away. Consult your veterinarian if you have any further inquiries regarding potential side effects.
METACAM shouldn’t be administered along with other NSAIDs or steroids, such as cortisone, prednisone, dexamethasone, or triamcinolone. Examples include aspirin, carprofen, etodolac, and deracoxib.
Inform your veterinarian of all medications you have given your dog in the past, as well as any you plan to administer along with METACAM. Included here should be additional medications that are available over the counter.
Your veterinarian may want to confirm that your dog can take all of its medications at the same time.
This sheet provides a summary of information about METACAM. Consult your veterinarian if you have any queries or worries about METACAM or the pain associated with osteoarthritis.
METACAM should only be administered to the dog for which it was prescribed, as with all prescription medications. METACAM Oral Suspension is for use in dogs only. Do not give METACAM Oral Suspension to cats. Your dog should only receive it for the condition for which it was prescribed. At routine checkups, it’s crucial to periodically talk about your dog’s reaction to METACAM. The best person to decide whether your dog is responding as expected and whether they should keep receiving METACAM is your veterinarian.
Attention: Under federal law, only a licensed veterinarian or someone acting on their behalf may use this medication.
Attention: Under federal law, only a licensed veterinarian or someone acting on their instruction may use this medication.
Item added to your cart Search the Relievet blog
As you observe your best friend stumbling, you can feel the stiffness starting to take over your body. Even though your dog is hurting, she still smiles because she is glad to see you. Although your relationship with your dog is unbreakable, you miss your outdoor activities together, such as hiking, playing fetch, and visiting dog parks in your neighborhood.
Your girl was recently diagnosed with Osteoarthritis. She was given the medication Meloxicam by the veterinarian, which can help her feel better and raise her quality of life. Like with any new medication, you are concerned about a number of potential negative effects.
This blog examines the benefits, risks, dosage, price, side effects, and alternatives of meloxicam.
An anti-inflammatory drug called meloxicam is used to treat pain and swelling in dogs who have osteoarthritis. It is very comparable to the drug Mobic, which is used to treat people’s pain and inflammation.
As long as a veterinarian prescribes Meloxicam for dogs, the FDA has given its approval.
Name-brand medication Mobic is typically only prescribed for humans. A veterinarian may prescribe generic meloxicam as well as the veterinary name brands Metacam and Loxicom for dogs.
Any person with osteoarthritis will tell you that it hurts if you ask them. If dogs could talk, they would tell you the same thing. Even if your best friend is unable to communicate his pain, you will probably notice if your dog exhibits signs of aching joints. Giving him painkillers like meloxicam is one way you can assist him.
Like all medications, meloxicam may cause side effects. The most common side effects are vomiting and decreased appetite. Call your vet immediately if you notice any side effects.
Less frequent adverse effects include skin rashes, skin irritation, jaundice, increased drinking, altered urination, changes in bowel habits, and unexpected weight loss. Stomach ulcers, unusual bleeding, loss of kidney function, and kidney failure are some of the most severe side effects.
Cuteness, the go-to website for devoted pet parents, provided this article. Your health, training, and behavior questions are all answered on Cuteness, along with the world’s cutest, funniest, and most heartwarming pet stories.
Meloxicam is a member of the oxicam class of non-steroidal anti-inflammatory drugs (NSAIDs). Meloxicam equivalent to one milligram is present in each milliliter of METACAM Oral Suspension. 5 milligrams and sodium benzoate (1. 5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide. The formulation is a viscous yellowish suspension with a honey-like smell.
METACAM should only be administered to the dog for which it was prescribed, as with all prescription medications. METACAM Oral Suspension is for use in dogs only. Do not give METACAM Oral Suspension to cats. Your dog should only receive it for the condition for which it was prescribed. At routine checkups, it’s crucial to periodically talk about your dog’s reaction to METACAM. The best person to decide whether your dog is responding as expected and whether they should keep receiving METACAM is your veterinarian.
Meloxicam was given orally at 1, 3, and 5X the recommended dose in a six-week target animal safety study, and no significant clinical adverse reactions occurred. All dose groups (control, 1, 3, and 5X the advised dose) of animals displayed some gastrointestinal distress (vomiting and diarrhea). Hematological, blood chemistry, urinalysis, clotting time, or buccal mucosal bleeding times did not show any treatment-related changes. One control dog, two dogs who received the 3X dose, and one dog who received the 5X dose all had stomach mucosal petechiae upon necropsy. Two dogs receiving the 5X dose and three dogs receiving the 1X dose both experienced areas of congested or depressed jejunal or ileal mucosa. In the control group, two additional dogs displayed comparable modifications. In dogs receiving the 3X dose, there were no macroscopic small intestinal lesions found. During the necropsy of two dogs given the 3X dose and two dogs given the 5X dose, renal enlargement was noted.
People should not take METACAM. Keep METACAM and all medication out of reach of children. Call your physician immediately if you accidentally take METACAM.
• Has experienced an allergic reaction to aspirin or other NSAIDs, such as hives, facial swelling, or red or itchy skin
FAQ
Is 15 mg of meloxicam too much for a dog?
giving canines meloxicam/metacam Humans are given much higher doses of this drug than canines. The smallest human dosage of Mobic is a 7. Even a 45-pound dog would only consume a quarter of the smallest human tablet, which is a 5. Your dog would most likely overdose if you gave it a whole Mobic tablet.
What happens if I give my dog too much meloxicam?
Toxic signs and symptoms include nausea, vomiting, diarrhea, and melena (black, tarry stools). These signs may occur within an hour of ingestion. Severe toxicity is indicated by the occurrence of seizures, tremors, and other symptoms of weakness.
Can I give my dog 2 doses of meloxicam?
Never administer two doses at once or extra doses to your pet.
Can human meloxicam be given to dogs?
A non-steroidal anti-inflammatory medication called meloxicam is used to treat pain and inflammation in both humans and dogs. Giving dogs the recommended dosage is safe, but caution should be used to prevent overdose. Meloxicam overdose can cause stomach ulcers and kidney failure. Protect yourself and your pet.